Show simple item record

dc.contributor.authorSuwan, Jiraporn
dc.contributor.authorTorelli, Amanda
dc.contributor.authorOnishi, Akihiro
dc.contributor.authorDordick, Jonathan S.
dc.contributor.authorLinhardt, Robert J.
dc.date2012
dc.date.accessioned2022-06-27T16:06:31Z
dc.date.available2022-06-27T16:06:31Z
dc.date.issued2012-11-01
dc.identifier.citationAddressing endotoxin issues in bioengineered heparin, J. Suwan, A. Torelli, A. Onishi, J. S. Dordick, R. J. Linhardt, Biotechnology and Applied Biochemistry, 59, 420-428, 2012.
dc.identifier.issn14708744
dc.identifier.issn8854513
dc.identifier.urihttps://doi.org/10.1002/bab.1042
dc.identifier.urihttps://hdl.handle.net/20.500.13015/5710
dc.descriptionBiotechnology and Applied Biochemistry, 59, 420-428
dc.descriptionNote : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
dc.description.abstractHeparin is a widely used clinical anticoagulant that is prepared from pig intestine. A contamination of heparin in 2008 has led to a reexamination of animal-derived pharmaceuticals. A bioengineered heparin prepared by bacterial fermentation and chemical and enzymatic processing is currently under development. This study examines the challenges of reducing or removing endotoxins associated with this process that are necessary to proceed with preclinical in vivo evaluation of bioengineered heparin. The current process is assessed for endotoxin levels, and strategies are examined for endotoxin removal from polysaccharides and enzymes involved in this process.
dc.description.sponsorshipNational Heart, Lung, and Blood Institute
dc.description.urihttps://login.libproxy.rpi.edu/login?url=https://doi.org/10.1002/bab.1042
dc.languageen_US
dc.language.isoENG
dc.relation.ispartofThe Linhardt Research Labs Online Collection
dc.relation.ispartofRensselaer Polytechnic Institute, Troy, NY
dc.relation.ispartofBiotechnology and Applied Biochemistry
dc.relation.urihttps://harc.rpi.edu/
dc.subjectBiology
dc.subjectChemistry and chemical biology
dc.subjectChemical and biological engineering
dc.subjectBiomedical engineering
dc.titleAddressing endotoxin issues in bioengineered heparin
dc.typeArticle
dcterms.accessRightshttps://login.libproxy.rpi.edu/login?url=https://doi.org/10.1002/bab.1042
dcterms.isPartOfJournal
dcterms.isVersionOfhttps://doi.org/10.1002/bab.1042
dc.rights.holderIn Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/
dc.creator.identifierhttps://orcid.org/0000-0003-2219-5833
dc.relation.departmentThe Linhardt Research Labs.
dc.relation.departmentThe Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
rpi.description.pages420-428
rpi.description.volume59


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record